Articles By Estel Grace Masangkay

  1. Roche To Build CHF450 Million Diagnostic Site In China 11/10/2014

    Roche announced its commitment to invest 450 million Swiss Francs to build a new diagnostic manufacturing facility in Suzhou, China over the next three years.

  2. Janssen's Olysio, Sofosbuvir Combo For HCV Earns FDA Nod Of Approval 11/10/2014

    Janssen Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted approval for Olysio (simeprevir) in combination with sofosbuvir as a once-daily, all-oral, interferon- and ribavirin-free treatment option for patients with genotype 1 chronic hepatitis C (CHC) infection.

  3. AstraZeneca Sells Lipodystrophy Drug Myalept To Aegerion 11/10/2014

    AstraZeneca announced that it has agreed to divest its orphan drug Myalept (metreleptin for injection) to Aegerion Pharmaceuticals.

  4. Sanofi Pasteur Posts Phase 3 Trial Results For Dengue Vaccine 11/7/2014

    Sanofi Pasteur announced the results of the company’s first landmark Phase 3 trial of its investigational dengue vaccine.

  5. AstraZeneca Completes Acquisition Of Almirall's Respiratory Business 11/7/2014

    AstraZeneca announced the completion of its acquisition of Almirall’s respiratory drugs franchise, containing a pipeline and a line of devices to treat lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).

  6. LabCorp To Acquire Covance For $6.1Billion 11/6/2014

    Laboratory Corporation of America Holdings (LabCorp), one of the largest medical testing companies in the U.S., announced that it will acquire drug development services firm Covance for an estimated $6.1 billion.

  7. Scientists ID New Therapeutic Target For Alzheimer's Drugs 11/5/2014

    A team of scientists at the Roskamp Institute reported that they have identified a new molecule that could be a new therapeutic target for drugs against Alzheimer’s disease.

  8. Sanofi's Label Update For Flu-Zone High-Dose Gets FDA Green Light 11/5/2014

    Sanofi’s vaccine division Sanofi Pasteur announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental biologics license application (sBLA) for its influenza vaccine Fluzone High-Dose.

  9. AstraZeneca And U Of Manchester Link In Drug Delivery Technologies 11/4/2014

    AstraZeneca and the University of Manchester announced that they have entered into a strategic partnership to develop cutting-edge drug delivery technologies.

  10. Pfizer's Antidepressant Pristiq May Not Harm Sexual Function 11/3/2014

    Pfizer posted favorable results from a post-marketing clinical study investigating the potential of antidepressant Pristiq to cause sexual dysfunction in patients with major depressive disorder (MDD).